Targeting serotonin transporter boosts tumor-fighting T cells.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 40645167.
- Also identified by DOI 10.1016/j.cell.2025.06.012.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this issue of Cell, Yang and colleagues demonstrate that autocrine activation of serotonin receptors on tumor-infiltrating CD8<sup>+</sup> T cells enhances antitumor immunity. Modulating serotonin signaling may provide a new approach to therapy for cancer. Serotonin-targeting drugs such as SSRIs and others, developed to fight depression, may thus be repurposed for cancer immunotherapy.
Medical subject headings
- CD8-Positive T-Lymphocytes
- Neoplasms
- Serotonin Plasma Membrane Transport Proteins